|
Jul 25
|
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
|
|
Jul 15
|
Sol-Gel Technologies Announces Management Realignment
|
|
May 20
|
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 20
|
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
|
|
May 16
|
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
|
|
Apr 1
|
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
|
|
Mar 14
|
Sol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
|
|
Mar 13
|
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
|
|
Nov 30
|
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
|
|
Nov 28
|
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
|